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in-stent restenosis, and we think that further investigations
are needed.
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Prognostic Value of Left Ventricular
Dyssynchrony in Patients With Heart Failure
Bader et al. (1) in a recent issue of the Journal reported on
the value of left ventricular (LV) dyssynchrony for the
prognostification of patients with severe heart failure (HF).
A large group of HF patients (n  104) with depressed
left ventricular ejection fraction (LVEF) (45%) was fol-
lowed up for one year. During this one-year period, 83% of
the patients were hospitalized for decompensated HF.
Based on multivariate Cox regression analysis, three vari-
ables predicted HF hospitalization: QRS width 140 ms,
LVEF 25%, and LV dyssynchrony (the mean LV dyssyn-
chrony was 68 44 ms). The patients included in the study
by Bader et al. (1) represent typical patients who may benefit
from cardiac resynchronization therapy (CRT). Recent
studies on CRT have shown improvement in symptoms,
quality-of-life score, exercise capacity, and LV systolic
function after CRT (2). Current selection criteria for CRT
include: severe HF (New York Heart Association functional
class III or IV), depressed LVEF (35%), and wide QRS
complex (120 ms). Careful analysis of the large clinical
trials, however, has revealed that 20% to 30% of patients do
not respond to CRT. Based on these observations, emphasis
has shifted toward a better selection of patients who may
benefit from CRT (3). Various studies have demonstrated
that LV dyssynchrony may predict response to CRT and,
therefore, the findings of Bader et al. (1) are of great
importance. Eventually, the identification of patients with
dyssynchrony may not only allow for optimal selection for
CRT but also may favorably affect the prognosis of these
patients. On the basis of their findings, do the authors feel
that the presence of dyssynchrony should be used to identify
patients who may benefit from CRT? And, if so, should the
region of latest activation before CRT be the preferred
location for the LV lead? This is of interest because
substantial percentage of patients in the study by Bader et al.
(1) exhibited other regions than the lateral wall as the latest
activation. This may then in turn raise the question whether
a surgical approach may sometimes be preferred rather than
transvenous implantation of the LV lead.
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REPLY
We thank Dr. Bax and colleagues for their interest in our
study (1) and, above all, for raising several important issues.
As they mentioned in their letter, various studies have
demonstrated or at least suggested that left ventricular (LV)
dyssynchrony might predict response to cardiac resynchro-
nization therapy (CRT). A recent study published in the
Journal (2) has showed that patients with a narrow QRS
complex and with LV electromechanical dyssynchrony
could benefit from CRT (even with a larger pacing-induced
QRS width compared with spontaneous rhythm) at the
same level of hemodynamic and clinical improvement than
patients with large QRS complexes (120 ms). These new
data can at least suggest that, independent of the QRS
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width, the presence of dyssynchrony is likely to be the key
point for selecting candidates to CRT. However, one issue
still remains: what is the best predictive echocardiographic
method (among the different Doppler tissue imaging tech-
niques) for selecting those patients? This requires larger
studies comparing the positive and negative predictive
values of several techniques already published.
From this point, it can be emphasized that heart failure
patients (New York Heart Association functional class III
or IV) with mechanical LV dyssynchrony should systemat-
ically benefit from CRT. So far, no study has clearly
demonstrated that medical treatment by itself could reduce
the level of ventricular dyssynchrony. If the future confirms
that drugs have no significant effect on ventricular dyssyn-
chrony, CRT should be applied systematically in such
patients.
Concerning the absence of relationship between the QRS
complex morphology and region of latest activation, we fully
agree with Bax et al. Ansalone et al. (3) already have
demonstrated that placing the LV pacing lead in regard to
the region of latest activation could further improve patients
benefiting from CRT. However, we think that this might be
suitable only in patients with primitive dilated cardiomyop-
athy. Indeed, by considering patients with severe ischemic
heart disease, regions with the latest activation could be
highly ischemic, so that pacing from such ventricular areas
could be first, potentially arrhythmogenic and second he-
modynamically detrimental because it might induce a new
dyssynchrony resulting from the low conduction velocity in
such regions. For that reason, further studies are crucially
needed to definitely state on this point.
Finally, we also agree that the best way to reach optimal
LV pacing sites should be the epicardial surgical approach
via thoracoscopy or mini-thoracothomy procedures. The
transseptal approach with endocardial LV pacing could also
be considered with the advantage of preserving the en-
dovenous approach and permitting free access to the four
ventricular walls.
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Serum Potassium Level and Risk
of Postoperative Atrial Fibrillation
in Patients Undergoing Cardiac Surgery
We read with great interest the article by MacDonald and
Struthers (1) in a recent issue of the Journal. The article
reports that potassium depletion is important in the patho-
genesis of cardiovascular disease and sudden cardiac death.
The authors suggest that avoiding hypokalemia is beneficial
in several cardiovascular disease states, including acute
myocardial infarction, heart failure, and hypertension. The
data linking hypokalemia with arrhythmia and cardiac arrest
in acute myocardial infarction are fairly strong (2–4).
We want to add atrial fibrillation (AF) after cardiac
surgery to the list of cardiovascular diseases where electro-
lyte imbalance may play an important pathogenetic role.
Although the etiology of AF after heart surgery is incom-
pletely understood, stimuli and triggers such as pre-existing
structural changes of the atria related to hypertension,
mechanical damage, volume overload, age, intraoperative
atrial ischemia, and pericardial lesions are thought to play a
role in the pathogenesis (5). Additionally, there seems to be
a significant increase in sympathetic tone in the postopera-
tive period in those patients who subsequently develop AF
(6). Hypokalemia causes cellular hyperpolarity, increases
resting potential, hastens depolarization, and increases au-
tomaticity and excitability (7). Thus, electrolyte imbalances
and hypokalemia may contribute to the etiology of postop-
erative AF (5,8). To test this hypothesis, we analyzed data
from the Study of Prevention of Postoperative Atrial Fibril-
lation (SPPAF), a randomized, double-blind, placebo-
controlled trial at a single tertiary care center of 253 patients
undergoing cardiac surgery. The study was designed to test
whether each of three active oral drug regimens—
amiodarone plus metoprolol, metoprolol alone, and so-
talol—is superior to placebo for prevention of AF after
cardiac surgery (9). Overall, 39.1% of the total study
population developed AF during the postoperative period.
Advanced age and surgery for heart valve disease increased,
and use of antiarrhythmic drugs, including beta-adrenergic
blockers, decreased the risk of postoperative AF by multi-
variate analysis (p  0.05). The rate of postoperative AF in
patients with serum potassium levels of 3.9 mmol/l or less,
compared with those with serum potassium levels of 4.4
mmol/l or greater were 50.7% and 32.9%, respectively (p 
0.05).
Thus, AF after cardiovascular surgery should be added to
a group of cardiovascular disease that may be adversely
influenced by low serum potassium concentrations. Addi-
tionally, potassium replacement may reduce the risk of
postoperative AF and should be tested prospectively in a
controlled clinical trial.
938 Letters to the Editor JACC Vol. 44, No. 4, 2004
August 18, 2004:936–40
